Xenon Pharmaceuticals Inc. has recently disclosed information in connection with its Annual Meeting of Shareholders, revealing key details for investors and stakeholders to take note of. The record date for notice, voting, and beneficial ownership determination has been set for April 5, 2024, with the meeting itself scheduled to take place on June 4, 2024.
Shareholders are entitled to notice and voting with respect to common shares, and the company has confirmed that it will pay for material distribution to objecting beneficial owners. Notably, Xenon Pharmaceuticals Inc. has opted not to utilize notice-and-access for both registered and non-registered investors.
These developments signify the company's commitment to transparent and inclusive shareholder engagement, as evidenced by the provision for objecting beneficial owner material distribution. The specified dates and entitlements provide clarity for shareholders and underscore the company's adherence to regulatory requirements and corporate governance standards. Today the company's shares have moved 0.2% to a price of $46.24. Check out the company's full 8-K submission here.